Hold Aurobindo Pharma, says Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "I personally hold Aurobindo Pharma; it is a disclosure. My family also holds Aurobindo Pharma. I believe that in terms of valuation, compared to the rest of the pharmaceutical companies, it is very attractively priced. Even if you see the numbers that they are reporting, the numbers are much better than the rest of the pharmaceuticals which have been reporting in the last quarter numbers also. So I see no reason to panic."

She further added, "The stock is definitely looking little bit weak, it has not been a performer over the last year, but at the same time, I would keep my hopes and continue holding."